The European landscape of listed biotech companies: 2018 review (Part 5)

[22] Trends in clinical success rates and therapeutic focus, Helen Dowden & Jamie Munro, Nature Reviews Drug Discovery, 08-05-2019
[23] The Changing Regulatory Landscape In China, Calliditas Therapeutics Half-year Report 2019, 15-08-2019
[24] The rewards of regulatory change, David Xie, Xiaofeng Li & An Li, Deloitte Inisghts, 18-04-2019

A vast majority of the company level data consolidated in this review are available on our intelligence service (subscription service for pro only). We provide small granularity data, and insights on the main items of biotech investing, for more than 150 companies listed on the main European markets. Disclaimer: we do not provide any investment recommendation on our service. This review is not aimed at supporting an investment decision on any company, any country, or any stock market mentioned in this report. See more details on

The author can be contacted via email, on Twitter @BertrandBio / @biotechradar_eu, or Linkedin.

Frontpage illustration generated on